Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MAIA Biotechnology, Inc. ( (MAIA) ) has issued an update.
On June 5, 2025, MAIA Biotechnology announced positive results from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer (NSCLC), showing a median overall survival of 17.8 months for patients treated with ateganosine (THIO) and Regeneron’s immune checkpoint inhibitor cemiplimab. This outcome is nearly triple the standard-of-care chemotherapy results and indicates a significant potential shift in NSCLC treatment. The company anticipates multiple regulatory pathways for accelerated FDA approval and exclusivity for ateganosine, potentially impacting its market positioning and offering new hope for patients resistant to existing therapies.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company’s lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 199,853
Technical Sentiment Signal: Sell
Current Market Cap: $53.04M
See more insights into MAIA stock on TipRanks’ Stock Analysis page.